Ezow7fw9qsq6jstppg7u ocello

OcellO

Leiden, ZH, NL

OcellO B.V. is a privately owned contract research organisation, which was founded in November 2011 based on technology developed at Leiden University.

OcellO is an innovative biotech company offering CRO services for the drug discovery industry that can significantly improve the efficiency of lead development. OcellO excels in the development of clinically relevant in vitro human micro-tissue models that can be used for the screening and profiling of small molecules and biologics. The analysis of these models, many of which use patient-derived material, is enabled by OcellO’s unique high throughput 3D imaging and phenotypic profiling technology. As well as providing measurements of cell growth and viability, phenotypic profiling allows the measurement of more complex biology that better correlates with clinical endpoints. Furthermore, compounds with the optimum therapeutic profile or optimum target specific profile... Show more »

OcellO B.V. is a privately owned contract research organisation, which was founded in November 2011 based on technology developed at Leiden University.

OcellO is an innovative biotech company offering CRO services for the drug discovery industry that can significantly improve the efficiency of lead development. OcellO excels in the development of clinically relevant in vitro human micro-tissue models that can be used for the screening and profiling of small molecules and biologics. The analysis of these models, many of which use patient-derived material, is enabled by OcellO’s unique high throughput 3D imaging and phenotypic profiling technology. As well as providing measurements of cell growth and viability, phenotypic profiling allows the measurement of more complex biology that better correlates with clinical endpoints. Furthermore, compounds with the optimum therapeutic profile or optimum target specific profile can be selected to enable a better ranking of compounds at early stage in the drug development process.

At OcellO we believe that sound collaboration and cutting edge science can speed up selection and development of clients lead compounds. We also welcome opportunities for partnerships, for example in Horizon 2020 projects. We are involved in several grant projects and are happy to work together!

« Show less

OcellO has not listed any services.

3D Tumor Model
Price on request

OcellO specialises in 3D culture models and high content amnalysis. OcellO excels in the development of clinically relevant in vitro human micro-tissue models that can be used for the screening and profiling of small molecules and biologics. The analysis of these models, many of which use patient-derived material, is enabled by... Show more »

OcellO specialises in 3D culture models and high content amnalysis. OcellO excels in the development of clinically relevant in vitro human micro-tissue models that can be used for the screening and profiling of small molecules and biologics. The analysis of these models, many of which use patient-derived material, is enabled by OcellO’s unique high throughput 3D imaging and phenotypic profiling technology.

3D screening models include:

Normal and cancer organoids
panel of 70 fully sequenced organoids licensed from the Hubrecht Institute.
Cystic fibrosis assay
panel of CFTR rectal organoids for forskolin-induced awelling assay (Dekkers,Clevers, and Beekman. Nature Methods 2013). Automated morphological assessment, high throughput format.
Polycystic kidney disease assay. 3D renal epithelial cyst swelling assay. Automated morphological assessment, high throughput format.
Ex vivo/in vitro patient derived xenograft 3D culture screening. High throughput and high content assays using the Charles River/Oncotest PDX collection.
Immune oncology models using cancer spheroids and HLA matched T cells. Automated morphological assessment of T cell infiltration and killing.

« Show less
Cell-Based Compound Screening
Price on request
Request a quote for more information about this service.
Organoids
Price on request
Request a quote for more information about this service.
3D Cell Culture Models
Price on request

OcellO specialises in 3D culture models and high content amnalysis. OcellO excels in the development of clinically relevant in vitro human micro-tissue models that can be used for the screening and profiling of small molecules and biologics. The analysis of these models, many of which use patient-derived material, is enabled by... Show more »

OcellO specialises in 3D culture models and high content amnalysis. OcellO excels in the development of clinically relevant in vitro human micro-tissue models that can be used for the screening and profiling of small molecules and biologics. The analysis of these models, many of which use patient-derived material, is enabled by OcellO’s unique high throughput 3D imaging and phenotypic profiling technology.

3D screening models include:

  • Normal and cancer organoids
  • panel of 70 fully sequenced organoids licensed from the Hubrecht Institute.
  • Cystic fibrosis assay
  • panel of CFTR rectal organoids for forskolin-induced awelling assay (Dekkers,Clevers, and Beekman. Nature Methods 2013). Automated morphological assessment, high throughput format.
  • Polycystic kidney disease assay. 3D renal epithelial cyst swelling assay. Automated morphological assessment, high throughput format.
  • Ex vivo/in vitro patient derived xenograft 3D culture screening. High throughput and high content assays using the Charles River/Oncotest PDX collection.
  • Immune oncology models using cancer spheroids and HLA matched T cells. Automated morphological assessment of T cell infiltration and killing.
« Show less
Compound Profiling
Price on request

The strength of OcellO’s 3D screening platform lies within the multi-dimensional, multi-parametric profiling of the microtissues by using our proprietary software toolset. By combining up to 900 different feature measurements, we can distinguish within one single assay between multiple different compound targets and address their... Show more »

The strength of OcellO’s 3D screening platform lies within the multi-dimensional, multi-parametric profiling of the microtissues by using our proprietary software toolset. By combining up to 900 different feature measurements, we can distinguish within one single assay between multiple different compound targets and address their specificity, mode of action and off-target effects.

Output

  • Dose-response curves
  • Compound classification
  • Insight into target specificity & MOA
  • Polypharmacology

Example: different compounds project differently in phenotypic space

These anti-cancer compounds are all ‘hits’ in viability assays but actually induce very different phenotypes. Compounds inducing specific phenotypes, such as reduced invasion or growth, can be identified and selected. Compounds that target the same pathway induce the same phenotype.

« Show less
Immuno-oncology Assays
Price on request

When testing immunotherapies, it is often critical to assess the functional cytotoxicity and infiltration capacity. In addition, immunomodulatory effects of new drugs in combination with already approved ones needs to be carefully assessed before these treatment modalities reach patients. However there are unlimited possibilities... Show more »

When testing immunotherapies, it is often critical to assess the functional cytotoxicity and infiltration capacity. In addition, immunomodulatory effects of new drugs in combination with already approved ones needs to be carefully assessed before these treatment modalities reach patients. However there are unlimited possibilities of new combinations, especially in the view of synergy effect observed with double checkpoint inhibition blockade. OcellO has developed a unique screening platform for immuno-oncology. This allows for efficient and cost effective testing of these combinations in assays that yield functional data on the tumour – immune system interplay.

OcellO’s screening platform is based on 3D co-cultures of cancer and immune cells. This 3D environment allows the different cell types to engage in a more realistic setting than when growing the cells in monolayer or mixing them in a suspension culture. Our proprietary OMiner® software platform enables discrimination of i) immune-tumour cell interactions and ii) drug-effects on the tumour and immune cells. This information, which cannot be obtained using conventional biochemical measurements, enables acquiring and automatic quantification of spatially resolved information that is of a critical importance for immuno-oncology studies.

Key advantages:

  • Automated analysis and robust quantification of T cell activation and invasion
  • Functional read-outs: active migration, association with tumoroids, cancer killing
  • Physiologically relevant micro-environment
  • Visualization of T cell interaction with the cancer
  • HLA-matched cell types
  • Enabling immuno-modulator combinations and synergy studies

OcellO offers cancer immunotherapy developers a new, highly powerful tool to select the most promising drugs at a very early stage in drug development. The availability of this new tool will empower the immunotherapy field, allowing the speedy progression of novel drugs towards clinical development – ultimately benefitting cancer patients.

« Show less
3D Cell-Based Assays
Price on request

OcellO specialises in generating models that closely recapitulate both healthy and disease phenotypes. Healthy tissues show normal functions, such as salt and water transport in kidney epithelial tubules or production of milk proteins by breast epithelial cells – functions that are lost in 2D cultures. In our disease models,... Show more »

OcellO specialises in generating models that closely recapitulate both healthy and disease phenotypes. Healthy tissues show normal functions, such as salt and water transport in kidney epithelial tubules or production of milk proteins by breast epithelial cells – functions that are lost in 2D cultures. In our disease models, tissues also show the expected disruption of phenotype and function that is associated with patient disease; cancer cells demonstrate dysplasia and become invasive, whereas epithelial cells from patients with cystic diseases show abnormal cyst formation. A more accurate simulation of the in vivo disease phenotype allows you to select more better quality molecules to progress through your discovery pipeline.

Using our disease models we can obtain various functional and clinical relevant readouts:

  • Proliferation, Migration and invasion
  • apico-basal polarity, dysplasia, lumen formation
  • Cyst swelling and transporter function

Over 150 models are available for screening of your compounds:

  • It is also possible to screen your compounds in panels of assays:
  • Panel of 30 patient-derived colorectal cancer and wt-organoids
  • Panel of 50 breast cancer cell lines
  • Lung, prostate and kidney carcinomas, osteosarcoma

In these models we can show whether the candidate compounds:

  • Restore the disease phenotype to a healthy state
  • Reduce the malignancy of cancer cells (inhibit invasion, inhibt growth or kill cells)
  • Increase sensitivity to existing anti-cancer therapies (drug combinations)

Advantage of testing compounds in a disease model:

  • Unbiased testing
  • Possibilities to identify new classes of compounds
  • Possibilities to identify new targets and pathways
« Show less
Ask A Question Find what you're looking for? If not, you can ask this lab a question:

OcellO has not received any ratings.

Be the first to endorse OcellO

Endorse this lab